Founded by pioneers in biopharmaceuticals with 50+ combined years of experience, Renova Therapeutics is developing a portfolio of definitive one-time gene therapy treatments as well as peptide therapies to restore health to people suffering from cardiovascular and metabolic diseases.
The Need
Congestive heart failure and type 2 diabetes afflict close to 400 million people worldwide, with incidence growing rapidly. These and several other chronic diseases pose an unsustainable burden on the lives of patients and their families, medical practitioners and economies overall.
Our Lead Product (RT-100)
A single dose of RT-100 – also known as AC6 gene transfer – has the potential to significantly improve heart function of CHF patients. Extensive preclinical research and Phase 2 trial results indicate that a one-time administration of RT-100 safely increases heart function beyond optimal heart failure therapy.
Our Paracrine Gene Therapy
Our proprietary paracrine gene therapy treatments are based on a novel systemic approach that introduces therapeutic genes capable of directing the body’s cells to work more normally. This single-IV injection approach is a foundation for products that may bring about substantial improvements in a variety of chronic cardiovascular and metabolic diseases.
